OUR PRODUCTS
Our Pipeline
We challenge ourselves to rethink the way medicines are developed,
and
are investing now to bring more value to patients in the future.
We strive for constant innovation and we are putting our passion and expertise to work in new areas.
SB16
Biosimilar candidate
- Molecule Denosumab
- Reference Biologic Prolia, Xgevaii
- Therapeutic Area Endocrinology
SB27
Biosimilar candidate
- Molecule Pembrolizumab
- Reference Biologic Keytrudaiii
- Therapeutic Area Oncology
*Pipeline last updated Aug 2025
- i
While SB16 is approved in the EU (and the UK), it will not be launched until after expiry of relevant SPCs(Supplementary Protection Certificates) protecting the Reference Biologics Prolia and Xgeva. Launch dates for ex-EU or ex-UK may vary depending on various factors, including expiry of relevant patent protection.
- ii
Prolia and Xgeva is a registered trademark of Amgen.
- iii
Keytruda is a registered trademark of Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, known as MSD outside the United States and Canada.
